Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

NCT07797244 is registered in ClinicalTrials.gov with Dai, Guanghai as lead sponsor.

NCT NCT07797244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07797244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)
Lead sponsor
Dai, Guanghai
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 29, 2026
Completion date
October 31, 2029
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ras-mutated colorectal cancer with liver metastases (crlm)